Platelet isoform of phosphofructokinase accelerates malignant features in breast cancer

The platelet isoform of phosphofructokinase (PFKP) is one of the key enzymes in the glycolytic pathway. PFKP is highly expressed in several cancers, and it has been reported to be involved in the progression of cancer cells. However, its oncological role in breast cancer (BC) remains unclear. The present study aimed to evaluate the function of PFKP in BC cells and its expression level in patients with BC. Firstly, the mRNA and protein expression of PFKP was evaluated in BC and non-cancerous mammary cell lines. Polymerase chain reaction (PCR) array analysis was conducted to evaluate the correlation between PFKP and 84 cancer-related genes. Then, PFKP knockdown was conducted using small interfering RNA, and cell proliferation, invasiveness and migration were analyzed. Furthermore, the association between PFKP mRNA expression and clinicopathological factors was investigated in 167 patients with BC. PFKP was highly expressed in estrogen receptor-negative and human epidermal growth factor receptor 2-negative BC cell lines. PCR array analysis demonstrated that the expression level of PFKP was significantly correlated with that of transforming growth factor-beta 1 and MYC proto-oncogene. PFKP knockdown significantly decreased the proliferation and invasiveness of MCF7, SK-BR-3, and MDA-MB-231 cells. Furthermore, cell migration was inhibited in SK-BR-3 and MDA-MB-231 cells. In the clinical specimens, patients with T2/T3/T4, lymph node metastasis, or stage II/III/IV exhibited higher expression of PFKP mRNA than patients with less severe disease. In conclusion, the present findings indicated that PFKP is involved in promoting tumor-progressive oncological roles in BC cells across different subtypes and is considered a possible novel therapeutic target for BC.

Automated summary

The present study found that PFKP plays a role in promoting tumor progression in breast cancer cells and is highly expressed in different subtypes of breast cancer. PFKP may be a potential therapeutic target for breast cancer.